Alphatec (ATEC) Expected to Announce Quarterly Earnings on Thursday

Alphatec (NASDAQ:ATEC - Get Free Report) is expected to be issuing its Q1 2025 quarterly earnings data after the market closes on Thursday, May 1st. Analysts expect Alphatec to post earnings of ($0.12) per share and revenue of $167.57 million for the quarter.

Alphatec (NASDAQ:ATEC - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.04). Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The business had revenue of $176.79 million for the quarter, compared to the consensus estimate of $172.74 million. On average, analysts expect Alphatec to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Alphatec Trading Up 2.0 %

ATEC stock traded up $0.22 during midday trading on Tuesday, reaching $11.35. The company's stock had a trading volume of 253,647 shares, compared to its average volume of 2,043,439. The business's 50-day simple moving average is $10.41 and its 200-day simple moving average is $9.76. The stock has a market cap of $1.64 billion, a PE ratio of -8.87 and a beta of 1.20. Alphatec has a 52 week low of $4.88 and a 52 week high of $13.79. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21.

Insider Buying and Selling at Alphatec

In other Alphatec news, CEO Patrick Miles sold 50,000 shares of the company's stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $12.03, for a total value of $601,500.00. Following the sale, the chief executive officer now owns 6,152,544 shares in the company, valued at $74,015,104.32. This represents a 0.81 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP David Sponsel sold 36,256 shares of the firm's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $11.42, for a total value of $414,043.52. Following the completion of the sale, the executive vice president now directly owns 735,074 shares of the company's stock, valued at approximately $8,394,545.08. The trade was a 4.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 272,113 shares of company stock worth $3,121,225 over the last quarter. 22.80% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of brokerages recently commented on ATEC. HC Wainwright reaffirmed a "buy" rating and set a $20.00 price objective on shares of Alphatec in a research note on Monday, April 14th. Needham & Company LLC restated a "buy" rating and set a $16.00 target price on shares of Alphatec in a report on Thursday, February 27th. StockNews.com upgraded Alphatec from a "sell" rating to a "hold" rating in a report on Friday, February 28th. Piper Sandler increased their price objective on Alphatec from $12.00 to $13.00 and gave the stock an "overweight" rating in a report on Thursday, February 27th. Finally, Barclays boosted their target price on Alphatec from $20.00 to $21.00 and gave the company an "overweight" rating in a research note on Wednesday, January 22nd. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $17.67.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.